CSI Market
Sign In | Register

Aquestive Therapeutics Inc (AQST) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access AQST quarterly Cash Flow →
The quarterly cash flow data below helps track how Aquestive Therapeutics Inc's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-83.78
Depreciation & amortization0.55
Amortization of Other Assets11.00
Increase (Decrease) in Deferred Revenue-0.57
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.13
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation7.62
Income (Loss) from Equity Method Investments0.00
Gain (Loss) on Contract Termination0.00
Provision For Doubtful Accounts And Allowance For Doubtful Accounts Receivable Write Offs-
Extinguishment Of Debt Gain Loss Net Of Tax-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts and Other Receivables-10.37
Increase (Decrease) in Accounts Payable19.52
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities3.03
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.70
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-52.43
Investing Activities
Capital Expenditures-0.56
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.56
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings-0.03
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.38
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-51.16
Proceeds From Sale Of Future Revenues Net-
Proceeds From Issuance Private Offering79.46
Proceeds From Issuance And Exercise Of Warrants-
Proceeds From Issuance Of Royalty Rights Agreements-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents71.55
Payments For Royalty Obligations-0.01
Payments For Royalty Obligations Financing Obligations-
Proceeds From Exercise Of Warrants Net1.43
Proceeds From Issuance Of Public Offering Issuance Of Warrants And Warrant Exercises-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities102.62
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-52.99
Total Cash Flow49.62
4 historic quarters locked

Sign in to unlock the full Aquestive Therapeutics Inc cash flow history.

Sign In Create Free Account

About Aquestive Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001398733-26-000018

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License